Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

Rhea-AI Summary

Axcella (Nasdaq: AXLA) announced plans to report its fourth quarter and full year 2020 financial results on March 17, 2021. The company will host a conference call at 8:30 a.m. ET, with details available on its website. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates targeting non-alcoholic steatohepatitis (NASH) and the recurrence of overt hepatic encephalopathy (OHE).

Positive

• Company plans to report financial results and business updates, indicating ongoing operations.
• Focus on innovative treatment for NASH and OHE could appeal to investors.

Negative

• None.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its fourth quarter and full year 2020 financial results and other business updates on March 17, 2021. The company will host a conference call at 8:30 a.m. ET that morning.

The conference call webcast will be available in the Investors & News section on the company’s website at www.axcellahealth.com. To access the call via telephone, please dial (844) 808-7139 (U.S. toll free) or (412) 902-0127 (international) five minutes prior to the start time. For those unable to listen in live, a webcast archive will be available on the company’s website for 90 days following the call.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors and News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005047/en/

FAQ

When will Axcella report its fourth quarter and full year 2020 financial results?

Axcella will report its financial results on March 17, 2021.

What time is Axcella's conference call regarding the financial results?

The conference call is scheduled for 8:30 a.m. ET on March 17, 2021.

How can I access Axcella's conference call?

The conference call can be accessed via telephone by dialing (844) 808-7139 for U.S. toll-free or (412) 902-0127 for international calls.

What are Axcella's main therapeutic candidates?

Axcella's pipeline includes candidates for non-alcoholic steatohepatitis (NASH) and overt hepatic encephalopathy (OHE) recurrence.